ABBV Up 5.5% in One Day, Should You Buy The Stock?

We believe there is a near-equal mix of good and bad in ABBV stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced. Here is our multi-factor assessment.

But no matter how attractive, investing in a single stock carries high risk. Trefis High Quality Portfolio and is designed to reduce stock-specific risk while giving upside exposure

Let’s get into details of each of the assessed factors but before that, for quick background: With $432 Bil in market cap, AbbVie provides pharmaceutical therapies including HUMIRA for autoimmune diseases, SKYRIZI for psoriasis, CREON for pancreatic insufficiency, and Synthroid for hypothyroidism in the United States.

[1] Valuation Looks Moderate

This table highlights how ABBV is valued vs broader market. For more details see: ABBV Valuation Ratios

[2] Growth Is Moderate

• AbbVie has seen its top line grow at an average rate of 0.6% over the last 3 years
• Its revenues have grown 6.1% from $55 Bil to $58 Bil in the last 12 months
• Also, its quarterly revenues grew 6.6% to $15 Bil in the most recent quarter from $14 Bil a year ago.

This table highlights how ABBV is growing vs broader market. For more details see: ABBV Revenue Comparison

[3] Profitability Appears Strong

• ABBV last 12 month operating income was $14 Bil representing operating margin of 23.5%
• With cash flow margin of 33.1%, it generated nearly $19 Bil in operating cash flow over this period
• For the same period, ABBV generated nearly $3.8 Bil in net income, suggesting net margin of about 6.5%

This table highlights how ABBV profitability vs broader market. For more details see: ABBV Operating Income Comparison

[4] Financial Stability Looks Strong

• ABBV Debt was $70 Bil at the end of the most recent quarter, while its current Market Cap is $432 Bil. This implies Debt-to-Equity Ratio of 16.3%
• ABBV Cash (including cash equivalents) makes up $6.5 Bil of $137 Bil in total Assets. This yields a Cash-to-Assets Ratio of 4.7%

[4] Downturn Resilience Is Moderate

ABBV saw an impact slightly better than the S&P 500 index during various economic downturns. We assess this based on both (a) how much the stock fell and, (b) how quickly it recovered.

2022 Inflation Shock

• ABBV stock fell 23.3% from a high of $174.96 on 8 April 2022 to $134.21 on 30 September 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
• However, the stock fully recovered to its pre-Crisis peak by 7 February 2024
• Since then, the stock increased to a high of $244.38 on 1 October 2025 $244.38

 
2020 Covid Pandemic

• ABBV stock fell 34.0% from a high of $97.79 on 12 February 2020 to $64.50 on 23 March 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
• However, the stock fully recovered to its pre-Crisis peak by 30 June 2020

But the risk is not limited to major market crashes. Stocks fall even when markets are good – think events like earnings, business updates, outlook changes. Read ABBV Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – S&P 500, Russell, and S&P midcap. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.